hydrocodone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1386 125-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hydrocodone
  • dihydrocodeinone
  • hydrocodon
  • multacodin
  • hydrocodone bitartrate
  • hydrocodone polistirex
Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant.
  • Molecular weight: 299.37
  • Formula: C18H21NO3
  • CLOGP: 1.13
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 38.77
  • ALOGS: -2.57
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 62.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.15 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 23, 1943 FDA ENDO PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 937.34 10.62 879 55677 144794 63287672
Cholecystitis chronic 465.18 10.62 213 56343 10148 63422318
Toxicity to various agents 392.97 10.62 751 55805 246499 63185967
Drug hypersensitivity 269.44 10.62 743 55813 309944 63122522
Cardio-respiratory arrest 254.55 10.62 290 56266 59669 63372797
Emotional distress 198.29 10.62 191 56365 32358 63400108
Cholelithiasis 178.88 10.62 208 56348 43717 63388749
Respiratory arrest 177.40 10.62 180 56376 32465 63400001
Contraindicated product administered 170.91 10.62 5 56551 217643 63214823
Drug abuse 166.98 10.62 260 56296 72258 63360208
Gallbladder disorder 165.45 10.62 136 56420 18706 63413760
Anxiety 157.25 10.62 488 56068 217053 63215413
Injury 151.37 10.62 250 56306 72997 63359469
Deep vein thrombosis 141.91 10.62 262 56294 83538 63348928
Maternal exposure during pregnancy 137.75 10.62 17 56539 220045 63212421
Drug intolerance 133.50 10.62 54 56502 308607 63123859
Hand deformity 123.93 10.62 4 56552 159453 63273013
Synovitis 123.16 10.62 12 56544 186906 63245560
Depression 121.43 10.62 418 56138 196074 63236392
Glossodynia 119.13 10.62 11 56545 178865 63253601
Systemic lupus erythematosus 115.25 10.62 23 56533 208895 63223571
Off label use 113.42 10.62 273 56283 674189 62758277
Infusion related reaction 109.35 10.62 41 56515 245480 63186986
Treatment failure 105.52 10.62 24 56532 199019 63233447
Intentional product misuse 105.05 10.62 192 56364 60725 63371741
Biliary dyskinesia 100.62 10.62 49 56507 2680 63429786
Pericarditis 93.49 10.62 6 56550 131573 63300893
Lower respiratory tract infection 88.45 10.62 8 56548 132299 63300167
Wound 80.15 10.62 23 56533 163240 63269226
Joint swelling 79.84 10.62 105 56451 327561 63104905
Gallbladder injury 79.11 10.62 34 56522 1389 63431077
Pulmonary embolism 78.89 10.62 256 56300 116428 63316038
Cardiac arrest 78.55 10.62 220 56336 92325 63340141
Drug ineffective 77.03 10.62 581 55975 1044184 62388282
Death 76.13 10.62 582 55974 373799 63058667
Discomfort 74.40 10.62 28 56528 167346 63265120
Drug withdrawal syndrome 70.36 10.62 103 56453 27091 63405375
Product use issue 64.26 10.62 61 56495 220459 63212007
Arthropathy 63.81 10.62 69 56487 234723 63197743
Accidental overdose 62.80 10.62 90 56466 23219 63409247
Accidental death 62.58 10.62 32 56524 1944 63430522
Rheumatoid factor positive 62.57 10.62 3 56553 84403 63348063
Helicobacter infection 60.97 10.62 6 56550 92779 63339687
Hepatic enzyme increased 58.91 10.62 56 56500 202272 63230194
Inadequate analgesia 58.34 10.62 35 56521 2908 63429558
Drug dependence 58.01 10.62 89 56467 24394 63408072
Overdose 57.71 10.62 229 56327 114849 63317617
C-reactive protein increased 57.57 10.62 8 56548 94699 63337767
Abdominal discomfort 53.63 10.62 130 56426 320755 63111711
Rash 53.37 10.62 288 56268 560583 62871883
Exposure during pregnancy 51.49 10.62 38 56518 155509 63276957
Drug abuser 48.40 10.62 31 56525 2892 63429574
Anhedonia 48.08 10.62 54 56502 10920 63421546
Muscle injury 46.34 10.62 3 56553 65342 63367124
Therapeutic product effect decreased 44.89 10.62 64 56492 193123 63239343
Coronary artery disease 43.60 10.62 92 56464 32285 63400181
Back pain 43.08 10.62 391 56165 263754 63168712
Gallbladder hypofunction 42.97 10.62 17 56539 561 63431905
Mental status changes 42.69 10.62 103 56453 39496 63392970
Folliculitis 42.59 10.62 6 56550 70311 63362155
Nasopharyngitis 42.47 10.62 103 56453 254154 63178312
Biliary colic 42.41 10.62 31 56525 3586 63428880
Condition aggravated 41.91 10.62 200 56356 402017 63030449
Cholecystitis 40.87 10.62 59 56497 15318 63417148
Neutropenia 40.63 10.62 58 56498 174947 63257519
Hypersensitivity 40.41 10.62 130 56426 292555 63139911
Scar 39.77 10.62 55 56501 13727 63418739
Alopecia 39.28 10.62 161 56395 337375 63095091
Cerebrovascular accident 37.63 10.62 193 56363 107831 63324635
Swelling 35.49 10.62 126 56430 275252 63157214
Insomnia 35.27 10.62 319 56237 214933 63217533
Rheumatoid arthritis 34.84 10.62 113 56443 253706 63178760
Respiratory depression 34.11 10.62 51 56505 13664 63418802
Infection 33.60 10.62 99 56457 229074 63203392
Cholesterosis 32.49 10.62 13 56543 442 63432024
Pyrexia 32.38 10.62 266 56290 470212 62962254
Acute lung injury 31.96 10.62 19 56537 1552 63430914
Febrile neutropenia 31.94 10.62 35 56521 118414 63314052
Intervertebral disc protrusion 31.49 10.62 67 56489 23642 63408824
Feeling abnormal 31.35 10.62 233 56323 148159 63284307
Gallbladder cholesterolosis 31.31 10.62 15 56541 791 63431675
Nausea 30.80 10.62 986 55570 853485 62578981
Sleep disorder due to general medical condition, insomnia type 30.38 10.62 5 56551 52212 63380254
Chest pain 29.93 10.62 309 56247 215650 63216816
Muscle spasms 29.01 10.62 238 56318 155912 63276554
Liver injury 28.82 10.62 9 56547 60511 63371955
Musculoskeletal stiffness 28.34 10.62 78 56478 184540 63247926
Drug screen positive 27.35 10.62 24 56532 3605 63428861
Dependence 27.11 10.62 19 56537 2058 63430408
Ill-defined disorder 27.01 10.62 20 56536 81735 63350731
Poisoning 25.93 10.62 45 56511 13655 63418811
Pain in extremity 25.56 10.62 426 56130 331060 63101406
Intervertebral disc degeneration 25.12 10.62 48 56508 15684 63416782
Dehydration 24.46 10.62 249 56307 173105 63259361
Product use in unapproved indication 23.68 10.62 81 56475 178999 63253467
Uterine perforation 23.49 10.62 30 56526 6933 63425533
Mental disorder 23.34 10.62 63 56493 25856 63406610
Thrombosis 22.75 10.62 116 56440 64639 63367827
Abnormal dreams 21.84 10.62 36 56520 10480 63421986
Fall 21.32 10.62 478 56078 391856 63040610
Thrombocytopenia 20.93 10.62 67 56489 151090 63281376
Cardiac failure 20.23 10.62 30 56526 89112 63343354
Migraine 19.99 10.62 159 56397 103187 63329279
Coagulopathy 19.58 10.62 51 56505 20493 63411973
Chronic obstructive pulmonary disease 19.11 10.62 108 56448 62578 63369888
Metabolic acidosis 18.92 10.62 85 56471 44984 63387482
Peripheral swelling 18.88 10.62 149 56407 265793 63166673
Cholecystectomy 18.83 10.62 34 56522 10643 63421823
Psoriatic arthropathy 18.70 10.62 33 56523 91487 63340979
Back injury 18.64 10.62 32 56524 9628 63422838
Withdrawal syndrome 18.40 10.62 49 56507 19948 63412518
Blister 18.35 10.62 57 56499 129757 63302709
Gamma-glutamyltransferase increased 18.22 10.62 4 56552 34027 63398439
Cholecystitis acute 18.14 10.62 29 56527 8231 63424235
Fear 18.06 10.62 42 56514 15724 63416742
Neck injury 17.97 10.62 15 56541 2106 63430360
Renal impairment 17.93 10.62 32 56524 88323 63344143
Restless legs syndrome 17.66 10.62 46 56510 18485 63413981
Purpura senile 17.49 10.62 9 56547 554 63431912
Tarsal tunnel syndrome 17.32 10.62 9 56547 565 63431901
Respiratory muscle weakness 17.24 10.62 6 56550 137 63432329
Interstitial lung disease 17.01 10.62 18 56538 61890 63370576
Red blood cell sedimentation rate increased 16.95 10.62 9 56547 43973 63388493
Hepatic function abnormal 16.85 10.62 6 56550 37136 63395330
Impaired healing 16.73 10.62 42 56514 102500 63329966
General physical health deterioration 16.64 10.62 108 56448 201294 63231172
Leukopenia 16.59 10.62 27 56529 77263 63355203
Tooth loss 16.35 10.62 25 56531 6831 63425635
Myocardial infarction 16.31 10.62 148 56408 99745 63332721
Abortion spontaneous 16.30 10.62 11 56545 47184 63385282
Memory impairment 16.28 10.62 153 56403 104105 63328361
Stomatitis 16.21 10.62 66 56490 138659 63293807
Peptic ulcer 15.85 10.62 20 56536 4567 63427899
Gastrooesophageal reflux disease 15.77 10.62 142 56414 95497 63336969
Emotional disorder 15.72 10.62 36 56520 13343 63419123
Wheezing 15.72 10.62 39 56517 95556 63336910
Cardiac failure congestive 15.63 10.62 138 56418 92295 63340171
Brain death 15.32 10.62 17 56539 3393 63429073
Device expulsion 15.24 10.62 6 56550 34916 63397550
Blood pressure systolic increased 15.13 10.62 12 56544 47385 63385081
Hepatocellular injury 15.11 10.62 3 56553 27378 63405088
Toxic leukoencephalopathy 15.06 10.62 9 56547 742 63431724
Irritable bowel syndrome 14.86 10.62 32 56524 82380 63350086
Lumbosacral plexopathy 14.78 10.62 3 56553 6 63432460
Cholestasis 14.70 10.62 4 56552 29430 63403036
Pulmonary infarction 14.65 10.62 15 56541 2732 63429734
Lactic acidosis 14.51 10.62 8 56548 38279 63394187
Drug-induced liver injury 14.40 10.62 9 56547 40213 63392253
Extradural haematoma 14.22 10.62 12 56544 1710 63430756
Nervousness 14.21 10.62 60 56496 30919 63401547
Hyperlipidaemia 14.17 10.62 44 56512 19527 63412939
Neuralgia 14.13 10.62 53 56503 25873 63406593
Osteonecrosis 14.09 10.62 51 56505 24479 63407987
Vestibular disorder 13.98 10.62 11 56545 1420 63431046
Pain 13.93 10.62 799 55757 739829 62692637
Accidental poisoning 13.84 10.62 8 56548 620 63431846
Drug interaction 13.76 10.62 134 56422 228997 63203469
Chronic kidney disease 13.69 10.62 78 56478 45320 63387146
Therapeutic product effect incomplete 13.69 10.62 61 56495 124995 63307471
Erythema 13.64 10.62 96 56460 175655 63256811
Major depression 13.47 10.62 25 56531 7993 63424473
Product complaint 13.46 10.62 33 56523 12776 63419690
Rotator cuff syndrome 13.36 10.62 34 56522 13468 63418998
Blood pressure fluctuation 13.25 10.62 13 56543 46304 63386162
Road traffic accident 13.13 10.62 66 56490 36566 63395900
Crying 12.95 10.62 48 56508 23295 63409171
Resorption bone increased 12.90 10.62 10 56546 1264 63431202
Muscle tightness 12.87 10.62 31 56525 11869 63420597
Septic shock 12.75 10.62 25 56531 66604 63365862
Tooth disorder 12.50 10.62 54 56502 28103 63404363
Hypoaesthesia 12.44 10.62 215 56341 168178 63264288
Spinal osteoarthritis 12.29 10.62 37 56519 16149 63416317
Brain oedema 12.28 10.62 34 56522 14161 63418305
Intestinal ischaemia 12.19 10.62 23 56533 7445 63425021
Unresponsive to stimuli 12.17 10.62 61 56495 33755 63398711
Nail growth abnormal 12.17 10.62 7 56549 538 63431928
Tendon disorder 12.13 10.62 20 56536 5823 63426643
Drug tolerance 12.09 10.62 22 56534 6927 63425539
Intervertebral disc disorder 12.03 10.62 18 56538 4825 63427641
Transverse sinus thrombosis 12.01 10.62 7 56549 551 63431915
Compression fracture 11.97 10.62 21 56535 6427 63426039
Nerve injury 11.95 10.62 27 56529 9919 63422547
Muscle atrophy 11.90 10.62 22 56534 7011 63425455
Blood potassium decreased 11.89 10.62 71 56485 41955 63390511
Live birth 11.87 10.62 4 56552 25626 63406840
Chronic fatigue syndrome 11.81 10.62 9 56547 1109 63431357
Psychological trauma 11.79 10.62 9 56547 1112 63431354
Aortic valve incompetence 11.77 10.62 20 56536 5968 63426498
Abdominal pain 11.64 10.62 343 56213 293113 63139353
Altered state of consciousness 11.57 10.62 4 56552 25226 63407240
Prescribed underdose 11.55 10.62 6 56550 29683 63402783
Gastrointestinal disorder 11.55 10.62 69 56487 131170 63301296
Fat intolerance 11.50 10.62 3 56553 24 63432442
Hyponatraemia 11.41 10.62 56 56500 111844 63320622
Malabsorption 11.37 10.62 16 56540 4056 63428410
Adverse drug reaction 11.26 10.62 35 56521 79679 63352787
Constipation 11.24 10.62 271 56285 224672 63207794
Brain herniation 11.10 10.62 15 56541 3662 63428804
Disease progression 11.09 10.62 64 56492 122694 63309772
Angioedema 11.02 10.62 16 56540 47949 63384517
Inflammation 11.01 10.62 37 56519 82236 63350230
Suicidal ideation 10.97 10.62 94 56462 62327 63370139
Screaming 10.92 10.62 14 56542 3248 63429218
Mitral valve prolapse 10.87 10.62 12 56544 2381 63430085
Electrocardiogram QT prolonged 10.82 10.62 23 56533 59507 63372959
COVID-19 10.74 10.62 58 56498 113045 63319421
Hyperkalaemia 10.66 10.62 20 56536 54183 63378283
Arteriosclerosis 10.65 10.62 26 56530 10040 63422426
Postinfarction angina 10.65 10.62 3 56553 33 63432433
Mitral valve incompetence 10.63 10.62 40 56516 19554 63412912

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 509.70 12.10 532 31277 97636 34827486
Toxicity to various agents 294.99 12.10 596 31213 199766 34725356
Accidental overdose 225.13 12.10 169 31640 19971 34905151
Drug abuse 195.78 12.10 335 31474 98761 34826361
Cardio-respiratory arrest 189.06 12.10 242 31567 55031 34870091
Drug dependence 161.91 12.10 151 31658 24066 34901056
Respiratory arrest 139.68 12.10 149 31660 27894 34897228
Drug abuser 115.31 12.10 61 31748 3893 34921229
Off label use 106.34 12.10 136 31673 419388 34505734
Overdose 103.88 12.10 245 31564 90814 34834308
Drug withdrawal syndrome 92.82 12.10 102 31707 19732 34905390
Intentional product misuse 70.66 12.10 139 31670 45472 34879650
Depression 69.33 12.10 220 31589 96878 34828244
Anxiety 67.12 12.10 221 31588 99207 34825915
Inadequate analgesia 62.48 12.10 37 31772 2938 34922184
Emotional distress 58.04 12.10 70 31739 14956 34910166
Cardiac arrest 52.21 12.10 199 31610 95960 34829162
Respiratory depression 47.58 12.10 66 31743 16179 34908943
Gun shot wound 46.46 12.10 22 31787 1106 34924016
Drug hypersensitivity 44.81 12.10 168 31641 80361 34844761
Insomnia 43.81 12.10 199 31610 103708 34821414
Coronary artery disease 38.68 12.10 114 31695 48191 34876931
Pyrexia 38.03 12.10 165 31644 332848 34592274
C-reactive protein increased 37.87 12.10 3 31806 54095 34871027
Death 36.36 12.10 535 31274 397514 34527608
General physical health deterioration 36.17 12.10 38 31771 128231 34796891
Myocardial infarction 35.14 12.10 209 31600 120876 34804246
Ventricular hypertrophy 33.24 12.10 30 31779 4577 34920545
Drug screen positive 33.13 12.10 28 31781 3915 34921207
Accidental death 32.86 12.10 23 31786 2433 34922689
Pain 32.41 12.10 306 31503 204369 34720753
Chest pain 31.92 12.10 211 31598 126551 34798571
Product use in unapproved indication 30.73 12.10 37 31772 117462 34807660
Drug tolerance 29.57 12.10 23 31786 2859 34922263
Drug interaction 29.53 12.10 106 31703 225840 34699282
Back pain 29.03 12.10 200 31609 121589 34803533
Substance abuse 28.53 12.10 35 31774 7606 34917516
Lumbar radiculopathy 27.41 12.10 14 31795 830 34924292
Laryngospasm 27.03 12.10 17 31792 1504 34923618
COVID-19 26.68 12.10 19 31790 77531 34847591
Dependence 25.99 12.10 15 31794 1135 34923987
Arteriosclerosis 25.60 12.10 42 31767 11926 34913196
Intervertebral disc protrusion 25.56 12.10 38 31771 9918 34915204
Hypoaesthesia 25.36 12.10 117 31692 61327 34863795
Condition aggravated 25.21 12.10 90 31719 192106 34733016
Intervertebral disc degeneration 24.95 12.10 30 31779 6387 34918735
Hepatic function abnormal 24.95 12.10 5 31804 44358 34880764
Cardiac failure 23.57 12.10 29 31780 91219 34833903
Pain in extremity 23.52 12.10 196 31613 126317 34798805
Renal impairment 23.42 12.10 31 31778 94482 34830640
Neutropenia 22.91 12.10 70 31739 156708 34768414
Spinal osteoarthritis 22.17 12.10 31 31778 7652 34917470
Interstitial lung disease 21.16 12.10 17 31792 65265 34859857
Acute kidney injury 21.08 12.10 177 31632 304811 34620311
Back injury 21.04 12.10 22 31787 4019 34921103
Febrile neutropenia 20.78 12.10 60 31749 136789 34788333
Pulmonary congestion 20.16 12.10 41 31768 13724 34911398
Mental status changes 19.97 12.10 78 31731 38005 34887117
Carpal tunnel syndrome 19.87 12.10 23 31786 4703 34920419
Poisoning 19.82 12.10 38 31771 12188 34912934
Environmental exposure 19.51 12.10 8 31801 284 34924838
Arteriosclerosis coronary artery 19.25 12.10 38 31771 12447 34912675
Antasthmatic drug level 19.07 12.10 5 31804 40 34925082
Hypoxic-ischaemic encephalopathy 18.96 12.10 22 31787 4510 34920612
Road traffic accident 18.82 12.10 46 31763 17404 34907718
Analgesic drug level 18.75 12.10 5 31804 43 34925079
Leukopenia 18.41 12.10 18 31791 62838 34862284
Foetal exposure during pregnancy 18.16 12.10 6 31803 38095 34887027
Rotator cuff syndrome 18.13 12.10 24 31785 5625 34919497
Nervousness 17.81 12.10 37 31772 12569 34912553
Gastrooesophageal reflux disease 17.76 12.10 75 31734 37849 34887273
Cardiomegaly 16.98 12.10 41 31768 15397 34909725
Plasma cell myeloma 16.57 12.10 79 31730 41958 34883164
Back disorder 16.52 12.10 25 31784 6626 34918496
Pulmonary oedema 16.39 12.10 86 31723 47443 34877679
Postictal state 16.19 12.10 10 31799 857 34924265
Walking disability 15.61 12.10 10 31799 913 34924209
Hyperlipidaemia 15.35 12.10 38 31771 14491 34910631
Burning sensation 15.28 12.10 44 31765 18350 34906772
Reaction to excipient 15.17 12.10 8 31801 507 34924615
Drug-induced liver injury 14.72 12.10 4 31805 28828 34896294
Mitral valve incompetence 14.66 12.10 38 31771 14905 34910217
Anger 14.64 12.10 33 31776 11851 34913271
Coronary artery stenosis 14.51 12.10 29 31780 9587 34915535
Complex regional pain syndrome 14.45 12.10 8 31801 559 34924563
Liver disorder 14.37 12.10 6 31803 32991 34892131
Blood cholesterol increased 14.13 12.10 46 31763 20497 34904625
Thymus disorder 14.12 12.10 3 31806 8 34925114
Irritability 14.12 12.10 52 31757 24638 34900484
Thrombocytopenia 14.03 12.10 84 31725 156163 34768959
Injury 13.94 12.10 46 31763 20641 34904481
Osteomyelitis 13.79 12.10 39 31770 16097 34909025
Lower respiratory tract infection 13.39 12.10 6 31803 31631 34893491
Phantom limb syndrome 13.38 12.10 6 31803 266 34924856
Bronchitis 13.17 12.10 74 31735 41889 34883233
Treatment failure 12.96 12.10 14 31795 46683 34878439
Groin pain 12.68 12.10 20 31789 5493 34919629
Dental caries 12.63 12.10 18 31791 4521 34920601
Peripheral vascular disorder 12.61 12.10 19 31790 5017 34920105
Decreased interest 12.56 12.10 13 31796 2347 34922775
Radiculopathy 12.48 12.10 14 31795 2767 34922355
Neutrophil count decreased 12.41 12.10 17 31792 51087 34874035
Seizure like phenomena 12.24 12.10 8 31801 756 34924366
Haemorrhoids 12.23 12.10 35 31774 14540 34910582
Drug use disorder 12.23 12.10 17 31792 4174 34920948

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1718.07 10.87 1512 65466 244255 79433155
Toxicity to various agents 729.43 10.87 1283 65695 420257 79257153
Cardio-respiratory arrest 553.15 10.87 562 66416 107948 79569462
Cholecystitis chronic 425.52 10.87 194 66784 9712 79667698
Drug abuse 385.03 10.87 572 66406 162119 79515291
Respiratory arrest 343.24 10.87 325 66653 57225 79620185
Accidental overdose 266.01 10.87 239 66739 39342 79638068
Emotional distress 240.72 10.87 227 66751 39742 79637668
Intentional product misuse 205.65 10.87 321 66657 94844 79582566
Drug hypersensitivity 189.85 10.87 617 66361 298299 79379111
Anxiety 181.89 10.87 539 66439 247973 79429437
Off label use 179.29 10.87 305 66673 906910 78770500
Injury 164.07 10.87 259 66719 77237 79600173
Gallbladder disorder 158.80 10.87 131 66847 19209 79658201
Cardiac arrest 156.29 10.87 404 66574 171692 79505718
Death 153.38 10.87 904 66074 565610 79111800
Depression 151.78 10.87 463 66515 216327 79461083
Drug abuser 148.87 10.87 81 66897 5932 79671478
Cholelithiasis 143.17 10.87 198 66780 52466 79624944
Overdose 142.82 10.87 408 66570 183798 79493612
Drug dependence 131.99 10.87 167 66811 40602 79636808
Contraindicated product administered 107.88 10.87 6 66972 157532 79519878
Drug withdrawal syndrome 107.32 10.87 139 66839 34579 79642831
Deep vein thrombosis 103.73 10.87 278 66700 120641 79556769
Biliary dyskinesia 100.41 10.87 47 66931 2498 79674912
Synovitis 99.44 10.87 7 66971 150727 79526683
Accidental death 98.51 10.87 55 66923 4236 79673174
Maternal exposure during pregnancy 94.11 10.87 5 66973 136533 79540877
Infusion related reaction 93.73 10.87 38 66940 230199 79447211
Drug intolerance 93.17 10.87 53 66925 264066 79413344
Coronary artery disease 92.14 10.87 183 66795 65291 79612119
Inadequate analgesia 84.18 10.87 51 66927 4578 79672832
Gallbladder injury 82.59 10.87 33 66945 1188 79676222
C-reactive protein increased 79.60 10.87 8 66970 129019 79548391
Respiratory depression 78.27 10.87 106 66872 27524 79649886
Pyrexia 74.20 10.87 306 66672 678403 78999007
Treatment failure 71.25 10.87 27 66951 170459 79506951
Hand deformity 71.00 10.87 4 66974 103915 79573495
Lower respiratory tract infection 70.18 10.87 12 66966 129208 79548202
Drug ineffective 62.63 10.87 594 66384 1080319 78597091
Joint swelling 55.83 10.87 98 66880 288548 79388862
Pericarditis 53.78 10.87 11 66967 104225 79573185
Systemic lupus erythematosus 52.63 10.87 18 66960 121131 79556279
Neutropenia 51.82 10.87 102 66876 287608 79389802
Chest pain 49.68 10.87 406 66572 281898 79395512
Insomnia 49.47 10.87 364 66614 244806 79432604
Glossodynia 49.15 10.87 13 66965 103324 79574086
Febrile neutropenia 48.80 10.87 74 66904 230925 79446485
Poisoning 48.73 10.87 81 66897 25191 79652219
Myocardial infarction 47.75 10.87 291 66687 183838 79493572
Mental status changes 47.69 10.87 144 66834 66815 79610595
Pulmonary embolism 47.53 10.87 276 66702 171378 79506032
Product use in unapproved indication 47.50 10.87 86 66892 250273 79427137
Back pain 47.00 10.87 425 66553 303755 79373655
Gallbladder hypofunction 44.85 10.87 17 66961 530 79676880
Gun shot wound 44.29 10.87 21 66957 1149 79676261
Condition aggravated 43.55 10.87 245 66733 500879 79176531
Drug screen positive 43.48 10.87 38 66940 6025 79671385
Cardiac failure 42.95 10.87 40 66938 154802 79522608
Cerebrovascular accident 42.54 10.87 249 66729 155043 79522367
Rash 41.44 10.87 300 66678 578058 79099352
Helicobacter infection 41.27 10.87 5 66973 69699 79607711
Renal impairment 40.07 10.87 44 66934 157739 79519671
Hypersensitivity 39.84 10.87 102 66876 262137 79415273
Interstitial lung disease 39.09 10.87 23 66955 112577 79564833
Exposure during pregnancy 39.05 10.87 18 66960 101114 79576296
Nasopharyngitis 37.61 10.87 100 66878 253781 79423629
Pain 37.28 10.87 812 66166 702990 78974420
Pain in extremity 36.95 10.87 468 66510 364070 79313340
Intervertebral disc protrusion 36.86 10.87 69 66909 23552 79653858
Scar 36.67 10.87 54 66924 15142 79662268
Product use issue 36.39 10.87 76 66902 209746 79467664
Rheumatoid factor positive 36.15 10.87 4 66974 59835 79617575
Drug interaction 35.50 10.87 204 66774 414979 79262431
Drug tolerance 35.41 10.87 40 66938 8635 79668775
Hepatic enzyme increased 35.28 10.87 62 66916 182548 79494862
COVID-19 34.77 10.87 49 66929 157625 79519785
Anhedonia 34.60 10.87 52 66926 14846 79662564
Thrombocytopenia 33.86 10.87 112 66866 265147 79412263
Ventricular hypertrophy 33.58 10.87 35 66943 6903 79670507
Hepatic function abnormal 33.27 10.87 10 66968 73097 79604313
General physical health deterioration 33.25 10.87 119 66859 275119 79402291
Biliary colic 32.86 10.87 27 66951 3935 79673475
Cholestasis 32.74 10.87 3 66975 52106 79625304
Leukopenia 32.42 10.87 30 66948 116483 79560927
Gamma-glutamyltransferase increased 32.18 10.87 4 66974 54676 79622734
Liver injury 31.30 10.87 5 66973 56609 79620801
Back injury 30.76 10.87 41 66937 10482 79666928
Drug reaction with eosinophilia and systemic symptoms 30.71 10.87 8 66970 64236 79613174
Arteriosclerosis 30.66 10.87 55 66923 18172 79659238
Dependence 30.06 10.87 21 66957 2401 79675009
Wound 29.93 10.87 32 66946 116147 79561263
Substance abuse 29.23 10.87 40 66938 10486 79666924
Gallbladder cholesterolosis 28.84 10.87 13 66965 633 79676777
Discomfort 28.74 10.87 38 66940 125579 79551831
Hyperlipidaemia 28.69 10.87 66 66912 26027 79651383
Feeling abnormal 28.53 10.87 230 66748 158969 79518441
Cholesterosis 28.37 10.87 11 66967 365 79677045
Folliculitis 28.24 10.87 6 66972 55374 79622036
Muscle injury 27.51 10.87 4 66974 48557 79628853
Eosinophilia 27.47 10.87 3 66975 45342 79632068
Uterine perforation 27.34 10.87 30 66948 6273 79671137
Gastrooesophageal reflux disease 27.16 10.87 165 66813 104081 79573329
Toxic epidermal necrolysis 26.88 10.87 3 66975 44578 79632832
Nervousness 26.80 10.87 75 66903 33340 79644070
Inflammation 26.25 10.87 24 66954 93729 79583681
Erythema 26.00 10.87 98 66880 223192 79454218
Road traffic accident 25.72 10.87 88 66890 43576 79633834
Rotator cuff syndrome 25.61 10.87 44 66934 14051 79663359
Muscle spasms 25.36 10.87 241 66737 174489 79502921
Cholecystitis 25.33 10.87 57 66921 22155 79655255
Drug-induced liver injury 25.16 10.87 12 66966 66105 79611305
Cholecystectomy 24.93 10.87 35 66943 9397 79668013
Hyponatraemia 24.88 10.87 72 66906 177776 79499634
Peripheral vascular disorder 24.57 10.87 32 66946 7998 79669412
Liver disorder 23.47 10.87 16 66962 72401 79605009
Infection 23.29 10.87 114 66864 241598 79435812
Intervertebral disc degeneration 23.26 10.87 45 66933 15740 79661670
Rash maculo-papular 23.22 10.87 9 66969 56069 79621341
Arteriosclerosis coronary artery 22.92 10.87 48 66930 17768 79659642
Blood pressure systolic increased 22.80 10.87 14 66964 66972 79610438
Coronary artery stenosis 22.72 10.87 39 66939 12445 79664965
Rheumatoid arthritis 22.67 10.87 94 66884 208376 79469034
Acute kidney injury 22.58 10.87 304 66674 519100 79158310
Therapeutic product effect decreased 22.44 10.87 67 66911 163796 79513614
Stomatitis 22.33 10.87 57 66921 146700 79530710
Sleep disorder due to general medical condition, insomnia type 21.64 10.87 5 66973 43551 79633859
Coagulopathy 21.59 10.87 73 66905 35933 79641477
Tarsal tunnel syndrome 21.46 10.87 10 66968 526 79676884
Acute lung injury 21.37 10.87 19 66959 3081 79674329
Spinal osteoarthritis 21.07 10.87 45 66933 16882 79660528
Mental disorder 21.05 10.87 66 66912 31236 79646174
Pulmonary congestion 20.93 10.87 60 66918 27040 79650370
Drug resistance 20.67 10.87 5 66973 42208 79635202
Blood pressure fluctuation 20.25 10.87 16 66962 67129 79610281
Mitral valve incompetence 19.93 10.87 61 66917 28504 79648906
Memory impairment 19.78 10.87 161 66817 111573 79565837
Hypoaesthesia 19.75 10.87 234 66744 179118 79498292
Lactic acidosis 19.71 10.87 18 66960 70341 79607069
Back disorder 19.55 10.87 35 66943 11543 79665867
Lumbar radiculopathy 19.53 10.87 15 66963 1984 79675426
Angina unstable 19.51 10.87 43 66935 16484 79660926
Antasthmatic drug level 19.46 10.87 5 66973 40 79677370
Thrombosis 19.35 10.87 129 66849 83971 79593439
Hyperkalaemia 19.35 10.87 42 66936 114356 79563054
Septic shock 19.23 10.87 47 66931 122754 79554656
Hepatocellular injury 19.11 10.87 8 66970 47585 79629825
Chronic obstructive pulmonary disease 19.05 10.87 130 66848 85289 79592121
Analgesic drug level 18.94 10.87 5 66973 45 79677365
Emotional disorder 18.79 10.87 39 66939 14348 79663062
Purpura senile 18.51 10.87 9 66969 521 79676889
Altered state of consciousness 18.20 10.87 7 66971 43815 79633595
Cardiomegaly 18.13 10.87 56 66922 26296 79651114
Multiple organ dysfunction syndrome 18.07 10.87 47 66931 120199 79557211
Epilepsy 17.86 10.87 6 66972 40854 79636556
Pneumocystis jirovecii pneumonia 17.68 10.87 3 66975 32505 79644905
Environmental exposure 17.66 10.87 8 66970 394 79677016
Chronic fatigue syndrome 17.47 10.87 12 66966 1335 79676075
Fear 17.29 10.87 49 66929 21937 79655473
Neutrophil count decreased 17.16 10.87 33 66945 93926 79583484
Bone marrow failure 16.96 10.87 11 66967 51096 79626314
Obstructive airways disorder 16.90 10.87 3 66975 31456 79645954
Pancytopenia 16.64 10.87 77 66901 165668 79511742
Major depression 16.27 10.87 28 66950 8952 79668458
Irritability 16.16 10.87 73 66905 41071 79636339
Migraine 15.99 10.87 127 66851 87366 79590044
Intervertebral disc disorder 15.98 10.87 20 66958 4805 79672605
Carpal tunnel syndrome 15.83 10.87 44 66934 19484 79657926
Multiple injuries 15.80 10.87 17 66961 3478 79673932
Withdrawal syndrome 15.71 10.87 54 66924 26800 79650610
Melaena 15.43 10.87 17 66961 60873 79616537
Suspected suicide 15.40 10.87 30 66948 10546 79666864
Neck injury 15.23 10.87 15 66963 2766 79674644
Red blood cell sedimentation rate increased 15.09 10.87 10 66968 45932 79631478
Wheezing 15.05 10.87 49 66929 116615 79560795
Musculoskeletal stiffness 14.92 10.87 86 66892 174922 79502488
Peptic ulcer 14.85 10.87 22 66956 6201 79671209
Extradural haematoma 14.81 10.87 15 66963 2861 79674549
Transaminases increased 14.78 10.87 13 66965 51730 79625680
Arthropathy 14.59 10.87 88 66890 177023 79500387
Anaphylactic shock 14.54 10.87 6 66972 35990 79641420
Postinfarction angina 14.51 10.87 4 66974 43 79677367
Angioedema 14.51 10.87 26 66952 76009 79601401
Pulmonary oedema 14.46 10.87 125 66853 88129 79589281
Cardiac failure congestive 14.46 10.87 183 66795 142219 79535191
Lymphopenia 14.23 10.87 4 66974 30553 79646857
Crying 14.06 10.87 47 66931 22996 79654414
Accident 14.03 10.87 26 66952 8805 79668605
Laryngospasm 13.94 10.87 17 66961 3980 79673430
Cardiogenic shock 13.93 10.87 9 66969 41905 79635505
Coronary artery occlusion 13.92 10.87 36 66942 15279 79662131
Drug eruption 13.85 10.87 10 66968 43925 79633485
Nausea 13.72 10.87 956 66022 956240 78721170
Psoriatic arthropathy 13.72 10.87 28 66950 77971 79599439
Head injury 13.72 10.87 65 66913 37304 79640106
Unresponsive to stimuli 13.71 10.87 87 66891 55701 79621709
Hypoxic-ischaemic encephalopathy 13.67 10.87 24 66954 7796 79669614
Copper deficiency 13.66 10.87 5 66973 141 79677269
Acute myocardial infarction 13.63 10.87 111 66867 76925 79600485
Prescribed underdose 13.50 10.87 4 66974 29510 79647900
Urticaria 13.25 10.87 96 66882 185105 79492305
Brain oedema 13.24 10.87 49 66929 25214 79652196
Opiates positive 13.15 10.87 9 66969 995 79676415
Anaphylactic reaction 13.15 10.87 32 66946 83711 79593699
Respiratory disorder 13.14 10.87 11 66967 44845 79632565
Musculoskeletal chest pain 12.95 10.87 48 66930 24716 79652694
Respiratory muscle weakness 12.89 10.87 6 66972 315 79677095
Neuropathy peripheral 12.86 10.87 178 66800 141127 79536283
Pulmonary infarction 12.82 10.87 16 66962 3833 79673577
Tooth loss 12.74 10.87 22 66956 7053 79670357
Pallor 12.66 10.87 14 66964 50048 79627362
Cholecystitis acute 12.62 10.87 32 66946 13419 79663991
Hepatitis 12.60 10.87 17 66961 55710 79621700
Heart rate decreased 12.58 10.87 25 66953 70291 79607119
Hernia 12.43 10.87 37 66941 17022 79660388
Laryngeal pain 12.33 10.87 20 66958 6094 79671316
Malabsorption 12.31 10.87 18 66960 5014 79672396
Anger 12.30 10.87 37 66941 17125 79660285
Restless legs syndrome 12.28 10.87 41 66937 20051 79657359
Blood pressure diastolic decreased 12.26 10.87 5 66973 30211 79647199
Transient ischaemic attack 12.23 10.87 81 66897 52614 79624796
Resorption bone increased 12.12 10.87 10 66968 1465 79675945
Phantom limb syndrome 12.11 10.87 6 66972 362 79677048
Toxic leukoencephalopathy 12.03 10.87 9 66969 1145 79676265
Dehydration 12.02 10.87 283 66695 247904 79429506
Eczema 11.97 10.87 10 66968 40808 79636602
Post concussion syndrome 11.94 10.87 7 66971 591 79676819
Muscle atrophy 11.90 10.87 28 66950 11204 79666206
Product complaint 11.74 10.87 31 66947 13318 79664092
Alopecia 11.70 10.87 131 66847 231224 79446186
Snake bite 11.68 10.87 3 66975 24 79677386
Peripheral swelling 11.62 10.87 158 66820 269459 79407951
Platelet count decreased 11.59 10.87 106 66872 194558 79482852
Therapeutic product effect increased 11.57 10.87 10 66968 1561 79675849
Polyneuropathy 11.55 10.87 3 66975 24148 79653262
Chronic kidney disease 11.53 10.87 95 66883 66059 79611351
Colitis 11.52 10.87 28 66950 73279 79604131
Transverse sinus thrombosis 11.26 10.87 7 66971 658 79676752
Amnesia 11.23 10.87 91 66887 62966 79614444
Osteomyelitis 11.22 10.87 56 66922 32809 79644601
Tendon disorder 11.22 10.87 21 66957 7165 79670245
Oxygen saturation decreased 11.22 10.87 63 66915 128984 79548426
Sepsis 11.21 10.87 159 66819 269269 79408141
Inappropriate schedule of product administration 11.21 10.87 66 66912 133562 79543848
Myofascial pain syndrome 11.18 10.87 11 66967 2026 79675384
Complex regional pain syndrome 11.13 10.87 11 66967 2037 79675373
Intentional overdose 11.11 10.87 137 66841 105823 79571587
Accidental poisoning 11.11 10.87 10 66968 1647 79675763
Panic attack 11.08 10.87 45 66933 24171 79653239
Stevens-Johnson syndrome 10.99 10.87 10 66968 39156 79638254

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05DA03 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
Opium alkaloids and derivatives
FDA MoA N0000000174 Opioid Agonists
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D000996 Antitussive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35482 narcotic analgesic
CHEBI has role CHEBI:51177 anti-tussive
CHEBI has role CHEBI:55322 mu-opioid agonists
FDA EPC N0000175690 Opioid Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Rhinitis indication 70076002 DOID:4483
Common cold indication 82272006 DOID:10459
Brain damage contraindication 2470005
Ocular hypertension contraindication 4210003 DOID:9282
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Hyperkalemia contraindication 14140009
Severe chronic ulcerative colitis contraindication 14311001
Constipation contraindication 14760008 DOID:2089
Mood swings contraindication 18963009
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Ventricular tachycardia contraindication 25569003
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hypercapnia contraindication 29596007
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Gastrointestinal perforation contraindication 51875005
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Blood coagulation disorder contraindication 64779008 DOID:1247
Arterial thrombosis contraindication 65198009
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Arteriosclerotic vascular disease contraindication 72092001
Diabetes mellitus contraindication 73211009 DOID:9351
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Urethral stricture contraindication 76618002
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Hiatal hernia contraindication 84089009 DOID:12642
Pulmonary emphysema contraindication 87433001
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Myasthenia gravis contraindication 91637004 DOID:437
Anemia due to enzyme deficiency contraindication 111577008
Acute abdominal pain contraindication 116290004
Gastrointestinal obstruction contraindication 126765001
Neoplasm of brain contraindication 126952004 DOID:1319
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Drug-induced psychosis contraindication 191483003 DOID:1742
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Coronary artery bypass graft contraindication 232717009
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Hyporeninemic hypoaldosteronism contraindication 236464008
Bladder outflow obstruction contraindication 236645006
Morbid obesity contraindication 238136002 DOID:11981
Rhabdomyolysis contraindication 240131006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Exacerbation of asthma contraindication 281239006
Pregnancy, function contraindication 289908002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Traumatic injury contraindication 417746004
Central nervous system depression contraindication 418072004
Dysfunction of sphincter of Oddi contraindication 430887001
Hypertensive urgency contraindication 443482000
Acute erosive gastritis contraindication 444926003
Smokes tobacco daily contraindication 449868002
Acute Thromboembolic Stroke contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.64 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
200MG/5ML;2.5MG/5ML OBREDON SOVEREIGN PHARMS N205474 Nov. 14, 2014 DISCN SOLUTION ORAL 10105324 Nov. 13, 2035 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
200MG/5ML;2.5MG/5ML OBREDON SOVEREIGN PHARMS N205474 Nov. 14, 2014 DISCN SOLUTION ORAL 9549907 Nov. 13, 2035 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
200MG/5ML;2.5MG/5ML OBREDON SOVEREIGN PHARMS N205474 Nov. 14, 2014 DISCN SOLUTION ORAL 9808431 Nov. 13, 2035 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST Ki 8.02 CHEMBL CHEMBL
Kappa-type opioid receptor GPCR AGONIST Ki 6.59 CHEMBL

External reference:

IDSource
4018165 VUID
N0000146502 NUI
D03725 KEGG_DRUG
34195-34-1 SECONDARY_CAS_RN
4018165 VANDF
4018473 VANDF
4019409 VANDF
C0020264 UMLSCUI
CHEBI:5779 CHEBI
CHEMBL1457 ChEMBL_ID
DB00956 DRUGBANK_ID
CHEMBL3989677 ChEMBL_ID
CHEMBL2062267 ChEMBL_ID
D006853 MESH_DESCRIPTOR_UI
5284569 PUBCHEM_CID
7081 IUPHAR_LIGAND_ID
1700 INN_ID
6YKS4Y3WQ7 UNII
142439 RXNORM
13945 MMSL
4835 MMSL
4836 MMSL
d03075 MMSL
001554 NDDF
001555 NDDF
001556 NDDF
20320002 SNOMEDCT_US
372671002 SNOMEDCT_US
3874004 SNOMEDCT_US
736862006 SNOMEDCT_US
CHEMBL1201470 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-0772 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-0772 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-0772 SOLUTION 7.50 mg ORAL ANDA 30 sections
Zamicet HUMAN PRESCRIPTION DRUG LABEL 2 0121-1542 SOLUTION 5 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-1544 SOLUTION 5 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-1544 SOLUTION 5 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-1544 SOLUTION 5 mg ORAL ANDA 30 sections
Zamicet HUMAN PRESCRIPTION DRUG LABEL 2 0121-2313 SOLUTION 10 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-2316 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-2316 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-2316 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-4772 SOLUTION 2.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-4772 SOLUTION 2.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-4772 SOLUTION 2.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Homatropine Methylbromide HUMAN PRESCRIPTION DRUG LABEL 2 0121-4811 SYRUP 5 mg ORAL ANDA 35 sections
TussiCaps HUMAN PRESCRIPTION DRUG LABEL 2 0187-0054 CAPSULE, EXTENDED RELEASE 5 mg ORAL ANDA 24 sections
TussiCaps HUMAN PRESCRIPTION DRUG LABEL 2 0187-0108 CAPSULE, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0410 TABLET 5 mg ORAL ANDA 37 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0410 TABLET 5 mg ORAL ANDA 37 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0411 TABLET 7.50 mg ORAL ANDA 37 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0411 TABLET 7.50 mg ORAL ANDA 37 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0412 TABLET 10 mg ORAL ANDA 37 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0412 TABLET 10 mg ORAL ANDA 37 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0254-2034 TABLET 5 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0254-2035 TABLET 7.50 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0254-2036 TABLET 10 mg ORAL ANDA 34 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0406-0123 TABLET 5 mg ORAL ANDA 28 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0406-0124 TABLET 7.50 mg ORAL ANDA 28 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0406-0125 TABLET 10 mg ORAL ANDA 28 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0406-0376 TABLET 5 mg ORAL ANDA 27 sections